Supplementary Materials

Supplementary Material for:

Hedgehog Agonist Therapy Corrects Structural and Cognitive Deficits in a Down Syndrome Mouse Model

Ishita Das, Joo-Min Park, Jung H. Shin, Soo Kyeong Jeon, Hernan Lorenzi, David J. Linden, Paul F. Worley, Roger H. Reeves*

*Corresponding author. E-mail:

Published 4 September 2013, Sci. Transl. Med. 5, 201ra120 (2013)
DOI: 10.1126/scitranslmed.3005983

This PDF file includes:

  • Notes
  • Fig. S1. SAG had mitogenic activity in primary GCP cultures.
  • Fig. S2. Dentate gyrus is not affected by SAG treatment.
  • Fig. S3. SAG treatment does not affect open-field performance.
  • Fig. S4. SAG treatment does not improve Y maze performance in Ts65Dn mice.
  • Fig. S5. SAG treatment normalizes search strategies of Ts65Dn mice in the MWM.
  • Table S1. Cerebellar morphological measurements.
  • Table S2. Dentate gyrus granule cell number at P6 (hematoxylin-stained).
  • Table S3. BrdU-positive cells in the DG at P6.
  • Table S4. Electrophysiological measurements from cerebellar Purkinje cells.
  • Table S5. Open-field activity.
  • Table S6. Total number of entries and percent alternation in Y maze.
  • Table S7. Latency in the MWM visible platform test (seconds).
  • Table S8. Latency in the MWM hidden platform test (seconds).
  • Table S9. Time spent in the correct quadrant in the MWM probe test (seconds).
  • Table S10. Strategy scores of animals in hidden platform test, by day and trial number.
  • Table S11. Relationship between FV amplitude and fEPSP slope.
  • Table S12. Paired pulse ratio.
  • Table S13. TBS-LTP enhanced by SAG in slices from Ts65Dn mice.
  • Table S14. Current-voltage relationship.
  • Table S15. NMDA/AMPA ratio.

[Download PDF]